Resetting the agenda for antibiotic resistance through a health systems perspective

2021-07-01

COVID-19 will not be the last pandemic - the next one is already here: antibiotic resistance. Lessons learnt from the COVID-19 pandemic can help mobilize urgent global action to address the silent pandemic of antibiotic resistance affecting countries throughout the world. Antibiotics are critical components of all health systems. In an article published online in The Lancet Global Health June 15, 2021, authors from the senior leadership of ReAct, argue that a health system approach nationally and globally is critical to mitigate the devastating consequences of antibiotic resistance. The article below is the full text published in Lancet Global Health.

Although the individual and societal consequences of antibiotic resistance spiral upwards, coordinated action has not kept pace on a global scale. The COVID-19 pandemic has highlighted the need for resilient health systems and has resulted in an unprecedented rate of collaboration in scientific, medical, social, and political dimensions. The pandemic has also created a renewed awareness of the importance of infectious diseases and is a substantial entry point for reigniting the momentum towards containing the silent pandemic of antibiotic resistance. In this Viewpoint, we discuss the limitations in the current narrative on antibiotic resistance and how it could be improved, including by concerted efforts to close essential data gaps. We discuss the need for capacity building and coordination at the national and global levels to strengthen the understanding of the importance of sustainable access to effective antibiotics for all health systems that could generate tangible links to current processes for global health and development.

Introduction

Otto Cars, Founder of ReAct, about the urgent need of resetting
the agenda for antibiotic resistance through a health systems perspective.

In 2001, WHO published a global strategy to contain antimicrobial resistance. A year later, a workshop identified several crucial barriers to the implementation of the strategy (eg, underdeveloped health infrastructures and scarcity of valid data); an action plan for continuing implementation of the strategy was therefore recommended. These challenges, many of which remain valid today, were discussed at the inaugural meeting of ReAct – an international network dedicated to the problem of antibiotic resistance — in 2005. 3 A global action plan on antimicrobial resistance, which spurred other political initiatives, was not adopted until 2015. Antibiotics are used more than any other class of antimicrobials, and in the political declaration on antimicrobial resistance in 2016, the UN General Assembly identified resistance to antibiotics as the greatest and most urgent global threat. This declaration was followed by the recommendations from the ad hoc UN Interagency Coordination Group on Antimicrobial Resistance (IACG) in 2019, and the formation of the One Health Global Leaders Group on antimicrobial resistance in 2020. The issue of antimicrobial resistance has featured in several health-related international agendas, such as the Global Health Security Agenda, International Health Regulations, UN Sustainable Development Goals, health systems strengthening, primary health care, and universal health coverage. However, the nature of antimicrobial resistance spanning diseases and sectors is a barrier to making a strong and sustained case, ultimately, to drive local impact. Substantial shortcomings remain in making investments, international collaboration, and collective action against antibiotic resistance proportionate to its global consequences.

The current COVID­19 pandemic has created a renewed awareness of the importance of infectious diseases, the speed at which health gains can be lost, and the need for resilient health systems. The pandemic offers opportunities to increase recognition that sustainable access to effective antibiotics is a fundamental component for both basic and specialized medicine, which is increasingly threatened by antibiotic resistance. However, when advancing action on antibiotic resistance, all stakeholders should reflect on the shortcomings of current messaging and advocacy, and move towards adapting and refocusing the message. Here, we have identified areas in which improvements could help reset the agenda on antibiotic resistance through a health systems perspective. A similar systems view is needed in the animal and environmental sectors with synergies sought between the three sectors.

The semantic barrier

The plethora of terms describing microbial drug resistance has created a language barrier, which continues to be discussed. We believe that the grouping of bacterial resistance with resistance in other microbes (ie, viruses, fungi, and parasites) under the umbrella of antimicrobial resistance has diffused the focus on antibiotic resistance. Although resistance is a problem with all antimicrobial drugs, antibiotics are used more than any other class of antimicrobials and need a more prominent position in the narrative. Although ReAct, the US Centers for Disease Control and Prevention, and the European Centre for Disease Prevention and Control are focusing on antibiotic resistance, WHO uses both antibiotic resistance and antimicrobial resistance, often interchangeably. Moreover, in 2020, World Antibiotic Awareness Week was renamed World Antimicrobial Awareness Week. Use of the term antimicrobial resistance could cause confusion as we believe that most people who use it are referring to antibiotic resistance, especially given its use in the One Health context. To avoid this equivocation, clarity is needed when antimicrobial resistance is discussed.

Evidence building to strengthen the narrative

How can relevant data help address antibiotic resistance?
Listen to Sujith J Chandy, Director ReAct Asia Pacific.

Resetting the agenda for antibiotic resistance needs to build on relevant data, informing both policymakers and the public about the serious consequences of a lack of effective antibiotics. Scarce data regarding the magnitude of the problem has been considered one of the biggest barriers for national champions to convince policymakers. A review on antimicrobial resistance estimated 700 000 annual deaths globally and 10 million deaths by 2050 from antimicrobial­ resistant infections. These infections included malaria and HIV, as well as tuberculosis and a few other bacteria, which has obscured the distinction between antimicrobial resistance and antibiotic resistance, and has created opportunities for criticisms regarding usefulness and reliability. Nevertheless, the figures from the antimicrobial resistance review have been uncritically used as an indicator of the burden of antibiotic resistance.

The first large study on the mortality and economic burden of antibiotic resistance was done in the EU by the European Centre for Disease Prevention and Control in collaboration with ReAct and estimated that there were 25 000 attributable deaths from antibiotic resistance in 2007. This study was later updated, giving an estimate of 33 110 attributable deaths. Although not fully comparable, national ­level data have also been published for the USA (35 900 deaths in 2019) and Thailand (19 122 deaths in 2010), yielding a annual total of 88 132 deaths from these regions, constituting approximately 10% of the world population.

Improved methodological approaches are needed to comprehensively estimate global deaths caused by antibiotic ­resistant infections. Access to nationally relevant surveillance data on resistance is also crucial. The Global Antimicrobial Surveillance System is an important initiative. However, the slow expansion of this system, especially in low-­income and middle­-income countries (LMICs), is concerning, with reports indicating that data from the surveillance system are not used nationally. Basic data generation on the resistance situation is needed, particularly in LMICs. A systematic review showed that a suitable report of bacterial resistance was absent from more than 40% of the countries in the African region. Furthermore, concerted efforts are required to develop tools for monitoring antibiotic use. Point prevalence studies are useful as initial steps to fill these gaps.

Changing patients’ demand for antibiotics is an important factor to reduce inappropriate antibiotic use. Reliable and understandable information on the detrimental and persisting effects of antibiotics on the commensal bacteria in our microbiomes could help to implement such behavioral change and reduce antibiotic use. Globally, there is a continuous shift towards the increase of resistant strains, with faecal carriage of extended­ spectrum beta­lactamase ­producing bacteria reaching 60–70% in some WHO regions by 2011. Although the carriage of resistant bacteria in the normal flora is not directly harmful, many infections are emanating from these flora. Such infections include wound, urinary tract, and invasive infections in people with cancer and other immunocompromised patients, making their treatment increasingly difficult as resistance in these bacteria becomes more common.

Another aspect to consider is that resistant bacteria are spreading globally through contacts between humans, animals, and the environment, via travel and trade. Although antibiotic resistance is not a disease per se, the pandemic dimensions are obvious and it could be described as an already ongoing silent pandemic driven by continuous selection of resistant bacteria in the microbiome. We believe that the current situation with COVID­19 is the appropriate time to start describing antibiotic resistance as a pandemic.

A health systems approach to antibiotic resistance

How can lessons from the COVID-19 pandemic facilitate understanding of the silent pandemic of antibiotic resistance?
Listen to Anthony D So Director ReAct North America.

The responses sparked by the COVID­19 pandemic span from an unprecedented collaboration for rapid innovation of diagnostics and vaccines, to increasing understanding of the need for preventive measures and equitable access to essential medicines and basic supplies. The same perspective needs to be applied to address the much less visible threat to all health systems caused by antibiotic resistance. As this problem will continue while health care is dependent on antibiotics, a long­term coordinated global and national response is needed in which gaps in crucial functions are minimised, avoiding a fragmented approach. This response must be an essential part of health systems strengthening, in which the implementation of national action plans (NAPs) is a key function. Countries were urged to develop such plans during the 2015 World Health Assembly at which the global action plan was adopted. NAPs were to be aligned with the objectives of the global action plan and put in place by 2017. The work on antibiotic resistance should have a strong and dedicated focus within a system­wide approach, and synergies should be sought with other national programmes, if appropriate.

Health system pillars to manage antibiotic resistance

We recognise four main pillars needed for implementing NAPs: prevention, data generation, access and conservation, and awareness and behavioral change (figure). Although activities addressing these areas are ongoing in many countries, they are often time­bound projects that are not integrated into national policies or systems. Such a fragmented approach is ineffective. A health systems approach for sustainable access to antibiotics implies not just coordinated specific actions, but concerted efforts towards human resources, universal health care, and optimal health­care infrastructure. A few examples of actions needed within these pillars in which lessons could be learned from the COVID­19 pandemic are explained further.

The COVID­19 pandemic generated unprecedented awareness regarding infection prevention including water, sanitation, and hygiene. A third of health­care facilities in low resource settings have little access to running water and soap for hand washing. Improvement in this area, triggered by the current pandemic, minimizes the risk for spread of resistant bacteria in these settings. There is also an urgent need to make existing bacterial vaccines available, and develop new ones for the prevention and control of antibiotic resistance.

COVID­19 proves that urgency enables science to be rapidly translated into action on the ground. The quick development of diagnostic tests allowed for tracing of individual cases and an unprecedented generation and dissemination of global data. Many countries do not have basic data on antibiotic resistance. Although investments are needed to fill this gap, very few donors have stepped up support. Investments will fall short if the data generated are not used effectively to inform not only global trends, but also national policies — eg, comparing antibiotic use data, updating treatment guidelines and essential medicines lists, optimizing procurement, educating health­care workers, and raising community awareness. An inexpensive rapid point ­of ­care diagnostic test would be a major game changer for reducing antibiotic misuse in viral conditions, including COVID­19 and influenza.

The COVID­19 pandemic has showed the world the impact of not having effective treatment or vaccines for infectious diseases, and the need for sustainable and equitable procurement and distribution channels once such technologies become available. Although access to effective antibiotics is an essential component of all health systems, the situation is complex, because expanding access needs to avoid excess use, but this is hampered by minimal laboratory diagnostic capacity, leading to inappropriate use and risk of treatment failure. Reliable supply of essential antibiotics will enable use of the WHO Access, Watch, Reserve (AwaRe) classification, thus optimising health­care spending and reducing risks for resistance development.

Why are powerful and contextualised awareness campaigns for behavioural change needed? Listen to Arturo Quizphe Peralta, Director ReAct Latin America.

Awareness campaigns have been instrumental in conveying important facts about COVID­19 to change the behavior of the general public. Although awareness campaigns on antibiotic resistance have been launched both globally and nationally, their effectiveness remain to be evaluated. As alluded to earlier, the narrative for antibiotic resistance needs drastic improvement to enable a strong civil society movement and political commitment. However, there is very little evidence for how this can be achieved, and for identifying the type of messaging that would be the most effective in the long term. Social and behavioral scientists need to be involved in developing and evaluating contextualized awareness campaigns.

National governance mechanisms

Securing the need for sustainable access to effective antibiotics must be part of a national governance mechanism at the highest decision making level. Approximately 80 countries have an NAP uploaded to the WHO library, and many countries have made substantial steps for their implementation. High-­income countries should lead by example; however, unnecessary antibiotic use remains high in many of these countries. A major problem, especially in LMICs, is the scarcity of incentives to fund and support implementation. A discussion document from the IACG identified five main barriers: political will, finance, coordination, monitoring, and data and technical capacity. A 2020 article discussed continuing challenges of NAP implementation in Africa and indicated that minimal allocations for NAPs in national budgets and absence of country and region-specific studies are major barriers. There is a wealth of supporting tools from WHO and other sources including the ReAct Toolbox. Efficient use of such tools requires sufficient human resources. However, many governments do not have full­time personnel to coordinate NAP activities; instead they have focal points fulfilling other duties concurrently.

Global action needed

What resources are needed to ensure sustainable access to effective antibiotics?
Listen to Anna Zorzet, Strategic Advisor, ReAct Europe.

Responsibility for securing equitable access to effective antibiotics in health­care systems falls on national governments, and NAP implementation should ultimately be financed from sources within a country as part of existing health budget lines. However, preserving lifesaving antibiotics must also be a global responsibility. The need for global governance is evident given the slow progress despite country commitments.

All countries need to come together in collective action and take greater responsibility for their domestic management of antibiotic use. High-­income countries must set an example and mobilise resources to support countries with weaker economies. WHO needs to strengthen its leadership by applying a health systems perspective on antibiotic resistance, with adequate resources to coordinate activities across programmes. An important priority for the Global Leaders Group on antimicrobial resistance should be to move implementation of the IACG recommendations forward and bring together donors globally to strengthen and coordinate funding streams to manage antibiotic resistance. In this way, the antibiotic resistance agenda can be reset, rekindling the agenda into a sustained movement.

There are two major areas for global collective action to transform failing systems towards sustainability: funding for capacity building and developing a sustainable global model for research and development of novel antibiotics and alternatives (figure). Antibiotic resistance has not been visible in the global funding landscape, and the absence of a go-­to-­place for countries to receive support is a critical barrier. Instead, countries have been seeking funding for smaller projects from different sources, complicating coordinated planning and implementation. Calls have been made for dedicated funds to address antibiotic resistance. The IACG recommendations urged existing financing mechanisms, such as the Global Fund to fight AIDS, tuberculosis, and malaria, to give the issue greater priority in their resource allocations, including assessing the need to expand their scope and mandate. Antibiotic resistance should be a powerful component in existing funding streams for the Sustainable Development Goals, universal health coverage, and water, sanitation, and hygiene. A newly established Multi­Partner Trust Fund on antimicrobial resistance will help fill some gaps in funding for capacity building, but currently only three countries have pledged support. Therefore, tangible funding for NAP implementation needs rapid expansion.

The first global analysis on the status of the antibiotic pipeline was a major contribution to the pivotal conference in 2009 (organised during the Swedish presidency of the EU) on new incentives for antibiotic development. The need for public sector involvement was clearly identified. However, more than a decade later, the antibiotic pipeline remains unresponsive to global needs. In the past 5 years, normative guidance, notably the Priority Pathogens List by WHO, has been developed. These guidelines aim to ensure that antibiotic research and development is needs ­driven. Although public and philanthropic investments supporting the development of antibacterial compounds have increased, coordinated public sector engagement with vision and intent is required to solve multiple shortcomings throughout the whole system. Major scientific challenges continue in early stages of drug discovery, and financing for preclinical and clinical development are neither sufficient nor targeted enough. Production, procurement, and access to new and old antibiotics all require novel approaches. Finally, increased focus must be given to the formidable challenge of introducing new antibiotics into health systems without propagating the historical mistakes of overuse and misuse of antibiotics while ensuring equitable access. Governments adopted the landmark UN Political Declaration on antimicrobial resistance in 2016, highlighting the importance of the principle of delinkage – ie, separating the cost of research and development from both the end product price and sales volume. This approach has yet to be implemented in a globally coordinated manner. There is an urgent need for governments to jointly define and take an end-­to-end approach towards reforming the system to ensure affordable sustainable access to those in need.

This year ReAct is celebrating 15 years of action on antibiotic resistance and this Lancet article is part of the celebration!

The story of ReAct started 15 years ago with a small group of people, many who are still with the network today. They all shared a passion for global health, and felt the urgency to address the growing problem of antibiotic resistance. The network has since grown, with the presence of offices in 5 continents and many passionate members working together.
Read more about ReAct 15 years celebrations and learn more about the story of ReAct!